Targets for Hyperparathyroidism

Hyperparathyroidism is characterized by dysregulation of parathyroid hormone (PTH) secretion and calcium homeostasis, leading to hypercalcemia and associated metabolic complications. Understanding the molecular targets directly implicated in this disease, such as Parathyroid Hormone (PTH), Parathyroid Hormone 1 Receptor (PTH1R), Calcium Sensing Receptor (CASR), Vitamin D Receptor (VDR), and Cytochrome P450 family 24 subfamily A member 1 (CYP24A1), is essential for unraveling the pathogenic mechanisms driving disease onset and progression. These targets are central to the regulation of calcium and phosphate metabolism, parathyroid gland function, and feedback loops involving vitamin D. Their study enables identification of actionable nodes for therapeutic intervention, such as calcimimetics acting on CASR or vitamin D analogs targeting VDR, and supports drug discovery by providing validated molecular endpoints. Collectively, these targets illuminate the pathophysiology of hyperparathyroidism, guide biomarker development, and underpin rational design of targeted therapies.

Calcium And Phosphate Homeostasis Regulators

This category encompasses targets directly involved in the regulation of calcium and phosphate metabolism and the feedback mechanisms that control parathyroid hormone secretion. These include Parathyroid Hormone (PTH), Parathyroid Hormone 1 Receptor (PTH1R), Calcium Sensing Receptor (CASR), Vitamin D Receptor (VDR), and Cytochrome P450 family 24 subfamily A member 1 (CYP24A1). Dysregulation of these proteins leads to abnormal PTH secretion, impaired calcium sensing, and altered vitamin D metabolism, which are hallmarks of hyperparathyroidism. These targets are mechanistically interconnected and collectively drive disease progression by disrupting mineral homeostasis.

Parathyroid Hormone (PTH)

Parathyroid Hormone (PTH) is an 84-amino acid peptide hormone secreted by the parathyroid glands, encoded by the PTH gene (Entrez: 5741, KEGG: 5741, UniProt: P01270). The mature protein contains an N-terminal domain essential for receptor binding and activation, and a C-terminal region involved in stability. PTH secretion is tightly regulated by serum calcium levels via the calcium sensing receptor (CASR). In hyperparathyroidism, dysregulated or autonomous PTH secretion leads to increased bone resorption, renal calcium reabsorption, and phosphate excretion, ultimately causing hypercalcemia and hypophosphatemia. PTH acts primarily through the Parathyroid Hormone 1 Receptor (PTH1R), activating cAMP and phospholipase C pathways. PTH is a validated therapeutic target, with interventions including surgical removal of parathyroid tissue and pharmacological agents like calcimimetics (which indirectly suppress PTH secretion via CASR activation). PTH measurement is a key biomarker for diagnosis and monitoring of hyperparathyroidism. Its pathogenic role is supported by clinical and genetic evidence showing that excessive or inappropriate PTH secretion is the primary driver of disease.

Parathyroid Hormone 1 Receptor (PTH1R)

Parathyroid Hormone 1 Receptor (PTH1R) is a class B G protein-coupled receptor encoded by the PTH1R gene (Entrez: 5745, KEGG: 5745, UniProt: Q03431). Structurally, PTH1R comprises an extracellular ligand-binding domain, seven transmembrane helices, and intracellular loops mediating G protein coupling. PTH1R is predominantly expressed in bone and kidney, where it mediates the biological actions of PTH and parathyroid hormone-related peptide (PTHrP). Upon PTH binding, PTH1R activates adenylate cyclase (cAMP) and phospholipase C signaling pathways, leading to increased bone resorption and renal calcium reabsorption. Mutations or dysregulation of PTH1R can modulate disease severity and tissue response to PTH. While PTH1R is not a direct therapeutic target in current clinical practice, its role is critical in the pathogenesis of hyperparathyroidism, and it is under investigation for potential pharmacological modulation. PTH1R function is essential for the downstream effects of PTH excess in hyperparathyroidism.

Calcium Sensing Receptor (CASR)

Calcium Sensing Receptor (CASR) is a G protein-coupled receptor encoded by the CASR gene (Entrez: 846, KEGG: 846, UniProt: P41180). The receptor has a large extracellular domain responsible for calcium binding, a seven-transmembrane domain, and intracellular C-terminal tail. CASR is highly expressed in parathyroid chief cells and the kidney. It functions as a key sensor of extracellular calcium concentration, regulating PTH secretion via intracellular signaling cascades (primarily Gq/11 and Gi/o pathways). Loss-of-function mutations in CASR cause familial hypocalciuric hypercalcemia and can contribute to primary hyperparathyroidism. Pharmacological activation of CASR with calcimimetics (e.g., cinacalcet) is an established therapy for secondary hyperparathyroidism and selected cases of primary hyperparathyroidism, acting to suppress PTH secretion. CASR is a validated drug target and genetic marker, and its pathogenic role is well supported by both Mendelian and acquired disease data.

Vitamin D Receptor (VDR)

Vitamin D Receptor (VDR) is a nuclear hormone receptor encoded by the VDR gene (Entrez: 7421, KEGG: 7421, UniProt: P11473). Structurally, VDR contains a DNA-binding domain (zinc finger motifs) and a ligand-binding domain for 1,25-dihydroxyvitamin D3 (calcitriol). Upon ligand binding, VDR heterodimerizes with RXR and regulates transcription of genes involved in calcium and phosphate absorption, bone remodeling, and feedback inhibition of PTH synthesis. Impaired VDR signaling reduces intestinal calcium absorption, leading to compensatory PTH secretion (secondary hyperparathyroidism). VDR agonists (vitamin D analogs) are used to treat secondary hyperparathyroidism, especially in chronic kidney disease. VDR is a key biomarker and therapeutic target, and its mechanistic importance in hyperparathyroidism is supported by genetic, biochemical, and clinical evidence.

Cytochrome P450 family 24 subfamily A member 1 (CYP24A1)

Cytochrome P450 family 24 subfamily A member 1 (CYP24A1) is a mitochondrial enzyme encoded by the CYP24A1 gene (Entrez: 1591, KEGG: 1591, UniProt: Q07973). The protein contains a heme-binding domain and catalyzes the 24-hydroxylation of 1,25-dihydroxyvitamin D3, thereby inactivating vitamin D metabolites. CYP24A1 activity is upregulated by elevated calcium and vitamin D levels, providing a negative feedback loop that limits vitamin D action and PTH suppression. Loss-of-function mutations in CYP24A1 can lead to hypercalcemia and suppressed PTH, while increased CYP24A1 activity may promote secondary hyperparathyroidism by reducing active vitamin D levels. CYP24A1 is not yet a direct drug target, but its modulation is under investigation as a means to optimize vitamin D therapy and control PTH levels. Its pathogenic role is supported by genetic and biochemical studies.